Patents Assigned to Orion Corporation
  • Patent number: 11098032
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: August 24, 2021
    Assignee: ORION CORPORATION
    Inventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • Patent number: 11046713
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: June 29, 2021
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • Patent number: 10870637
    Abstract: The present disclosure relates to an improved process for the preparation of a sulfonamide structured kinase inhibitor, namely N-(2?,4?-difluoro-5-(5-(1-methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-1-yl)-[1,1?-biphenyl]-3-yl)cyclopropanesulfonamide (1A) and pharmaceutically acceptable salts thereof. Compound of formula (1A) is a selective inhibitor of FGFR/VEGFR kinase families and is useful in the treatment of cancer.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: December 22, 2020
    Assignee: ORION CORPORATION
    Inventors: Oskari Karjalainen, Pekka Pietikäinen
  • Patent number: 10857120
    Abstract: The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising (i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount ranging from 25 mg to 150 mg or a therapeutically equivalent amount of another aromatic amino acid decarboxylase inhibitor, and (iii) entacapone in an amount ranging from 50 mg to 300 mg, wherein the proportion of entacapone to carbidopa in said dosage form ranges from 0.3:1.0 to 3.2:1.0 by weight, a moderately potent COMT inhibitor in an amount ranging from 25 mg to 200 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.16:1.0 to 3.08:1.0 by weight, or a highly potent COMT Inhibitor in an amount ranging from 1 mg to 100 mg, wherein the proportion of said COMT inhibitor to carbidopa in said dosage form ranges from 0.006:1.0 to 1.54:1.0 by weight.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: December 8, 2020
    Assignee: ORION CORPORATION
    Inventors: Juha Rouru, Mikko Kuoppamäki, Juha Ellmen, Pekka Männistö
  • Patent number: 10835515
    Abstract: The present disclosure relates to solid crystalline forms of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.
    Type: Grant
    Filed: July 1, 2019
    Date of Patent: November 17, 2020
    Assignee: ORION CORPORATION
    Inventors: Olli Törmäkangas, Terhi Heikkinen
  • Patent number: 10780079
    Abstract: The invention relates to a method for alleviating noise aversion in animals, particularly dogs, comprising administering to a subject in need thereof an effective amount of dexmedetomidine, medetomidine or a pharmaceutically acceptable salt thereof as the active ingredient. The active ingredient is preferably administered oromucosally, e.g. in the form of an oromucosal gel.
    Type: Grant
    Filed: October 14, 2013
    Date of Patent: September 22, 2020
    Assignee: ORION CORPORATION
    Inventors: Johanna Kokkonen, Mira Korpivaara, Nina Sarén
  • Patent number: 10774074
    Abstract: Compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 15, 2020
    Assignee: ORION CORPORATION
    Inventors: Shouming Wang, Esa Kumpulainen, Jarmo Pystynen, Antti Pohjakallio, Anssi Haikarainen
  • Patent number: 10717726
    Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: July 21, 2020
    Assignee: ORION CORPORATION
    Inventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
  • Patent number: 10711013
    Abstract: The present disclosure relates to compounds of formula (I), and pharmaceutically acceptable salts thereof. The present disclosure also relates to compositions and methods of treating comprising compounds of formula (I), and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: July 14, 2020
    Assignee: ORION CORPORATION
    Inventors: Gerd Wohlfahrt, Olli Törmäkangas, Harri Salo, Iisa Höglund, Arja Karjalainen, Pia Koivikko, Patrik Holm, Sirpa Rasku, Anniina Vesalainen
  • Patent number: 10590118
    Abstract: The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: March 17, 2020
    Assignee: ORION CORPORATION
    Inventors: Susanta Samajdar, Chandrasekhar Abbineni, Sanjita Sasmal, Subramanya Hosahalli
  • Publication number: 20190292170
    Abstract: Compounds of formula I, wherein A is an optionally substituted five-membered unsaturated heterocyclic ring containing 1, 2, or 3 N, O, or S ring heteroatom(s) exhibit alpha2C antagonistic activity and are thus useful for the treatment of diseases or conditions of the peripheric or central nervous system.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 26, 2019
    Applicant: ORION CORPORATION
    Inventors: Shouming WANG, Esa KUMPULAINEN, Jarmo PYSTYNEN, Antti POHJAKALLIO, Anssi HAIKARAINEN
  • Patent number: 10391082
    Abstract: A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: August 27, 2019
    Assignee: Orion Corporation
    Inventors: Tero Linnanen, Gerd Wohlfahrt, Srinivas Nanduri, Ravi Ujjinamatada, Srinivasan Rajagopalan, Subhendu Mukherjee
  • Patent number: 10383853
    Abstract: The present disclosure relates to solid crystalline forms of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: August 20, 2019
    Assignee: Orion Corporation
    Inventors: Olli Törmäkangas, Terhi Heikkinen
  • Patent number: 10376494
    Abstract: The present disclosure relates to solid crystalline forms of N—((S)-1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)-propan-2-yl)-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide (I) and the diastereomers thereof, and to methods for preparing such crystalline forms. Compound (I) and the diastereomers thereof are potent androgen receptor (AR) modulators useful as a medicament.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: August 13, 2019
    Assignee: Orion Corporation
    Inventors: Olli Törmäkangas, Terhi Heikkinen
  • Patent number: 10357492
    Abstract: The present invention relates to a method of treating motor neuron diseases such as amyotrophic lateral sclerosis (ALS) using levosimendan or its active metabolite (II) as an active ingredient. Levosimendan or its active metabolite (II) are able to relieve the loss of skeletal muscle strength or function associated with motor neuron diseases.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: July 23, 2019
    Assignee: Orion Corporation
    Inventor: Ken Lindstedt
  • Patent number: D899262
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: October 20, 2020
    Assignee: Orion Corporation
    Inventors: Eun Je Choe, Sock Woo Lee
  • Patent number: D899263
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: October 20, 2020
    Assignee: Orion Corporation
    Inventors: Eun Je Choe, Sock Woo Lee
  • Patent number: D899264
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: October 20, 2020
    Assignee: Orion Corporation
    Inventors: Eun Je Choe, Sock Woo Lee
  • Patent number: D899939
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: October 27, 2020
    Assignee: Orion Corporation
    Inventors: Eun Je Choe, Sock Woo Lee
  • Patent number: D922869
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: June 22, 2021
    Assignee: ORION CORPORATION
    Inventor: Eun Je Choe